2M Group operation Surfachem has officially opened its new formulation laboratory within the 3M Buckley Innovation Centre within the University of Huddersfield, UK, where it has been active since 2014. Mottie Kessler, CEO and chairman of 2M, was among those present to showcase formulation demonstrations within the personal care and home care laboratories

PharmaZell, a German-based producer of speciality APIs, and France’s CDMO Groupe Novasep are to merge under the ownership of PharmaZell’s current majority shareholder, private equity firm Bridgepoint. This remains subject to consultation with employees and other closing conditions.

Inotiv, a US CRO specialising in nonclinical and analytical drug discovery and development services, has reached an agreement to acquire research models and services Envigo. The cash and shares deal gives UK-headquartered Envigo an enterprise value of about $545 million, and the combined company one of around $1.2 billion.

ECHA has published the first database of substances of very high concern in products (SCIP) in the EU. This aims to enable consumers “to make more informed purchasing choices and help waste operators to further develop the re-use of articles and the recycling of materials,” the agency said.

Oslo-based biotech Circa Group has signed an agreement with French energy producer GazelEnergie. Under this, it will repurpose the former Emile Huchet coal-fired power station site, adjacent to the Carling Saint-Avold platform in north-eastern France, to make its Cyrene brand of renewable solvent at commercial scale.

CEM and AmbioPharm, two firms based in the Carolinas, have formed a partnership for the production of GMP peptides for the pharmaceutical industry. Under this, AmbioPharm will have exclusive rights to use CEM’s large-scale microwave technology for solid-phase peptide synthesis (SPPS) at up to multi-kilogram quantities using proprietary scalable reactors.

At its virtual capital markets day on 9 September, Merck KGaA announced that it aims to increase group sales by 6%/year to about €25 billion/year by 2025. To this end, investment, which will increase by 50% in the  years 2021-2025 compared to 2016-2020.

“We will continue to consistently and purposefully invest in areas that make us strong,” said CEO and executive board chair Belén Garijo (pictured). Merck will also seek targeted acquisitions, which are most likely to be small to medium-sized.